APA (7th ed.) Citation

Ellmark, P., Yachnin, J., Carneiro, A., Schultz, L., Hahn, A., Ambarkhane, S., . . . Ullenhag, G. J. First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Ellmark, Peter, Jeffrey Yachnin, Ana Carneiro, Lena Schultz, Amanda Hahn, Sumeet Ambarkhane, Karin Enell Smith, and Gustav J. Ullenhag. First-in-human, Multicenter, Open-label, Phase I Study of ATOR-1017 (evunzekibart), a 4-1BB Antibody, in Patients with Advanced Solid Malignancies. BMJ Publishing Group.

MLA (9th ed.) Citation

Ellmark, Peter, et al. First-in-human, Multicenter, Open-label, Phase I Study of ATOR-1017 (evunzekibart), a 4-1BB Antibody, in Patients with Advanced Solid Malignancies. BMJ Publishing Group.